BioSpace News Archive

GenSight Biologics announced initial results of new meta-analyses in Leber Hereditary Optic Neuropathy, which show those treated with LUMEVOQ® gene therapy experienced a rate of visual recovery greater than that of idebenone-treated patients and untreated patients.

Dassault Systèmes announced it collaborated with CDR-Life, a Swiss biotherapeutics company, to accelerate CDR-Life’s development of next-generation highly tumor-selective immunotherapies using CDR-Life’s proprietary M-gager® platform.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain.

Regulus Therapeutics Inc. announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors.

Regulus Therapeutics Inc. announced positive topline results from the second cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.

Zomedica Corp. announced the presentation of veterinary education programs scheduled at the upcoming Fetch dvm360 Veterinary Conference and subsequent dvm360 Fetch programs.

Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.

Enveric Biosciences announced that, on March 5, 2024, the United States Patent and Trademark Office issued U.S. Patent No. 11,918,594, titled “Multi-Substituent Psilocybin Derivatives” and is further expected to issue, on March 19, 2024, U.S. Patent No. 11,931,338, titled “Nitrilated Psilocybin Derivatives”.

Siolta Therapeutics, a clinical-stage biotech company, has announced the completion of a $12 million Series C financing round.

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced that the Company’s executive management is scheduled to present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 11:15 a.m. Eastern time.